These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27379812)

  • 1. Clinical use of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
    [No Abstract]   [Full Text] [Related]  

  • 2. The science of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
    [No Abstract]   [Full Text] [Related]  

  • 3. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Therapy in Melanoma.
    Callahan MK
    Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 7. Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
    El Rassy E; Assi T; Kattan J
    Future Oncol; 2017 Feb; 13(5):381-383. PubMed ID: 27884060
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune Checkpoint Therapies in Prostate Cancer.
    Goswami S; Aparicio A; Subudhi SK
    Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
    Campbell MT; Siefker-Radtke AO; Gao J
    Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are virus-induced cancers more sensitive to checkpoint inhibitors?
    Kanaan H; Kourie HR; Awada AH
    Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
    Pal SK; Hu A; Chang M; Figlin RA
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Therapy in Head and Neck Cancers.
    Msaouel P; Massarelli E
    Cancer J; 2016; 22(2):108-16. PubMed ID: 27111906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.